Clinical characteristics of patients with COVID-19-associated mucormycosis (CAM) hospitalized at Shafa Hospital, Kerman: 2022
Related Experiment Video
Updated: Jun 26, 2026

Transient Transduction of the Strobilated Forms of Echinococcus granulosus
Published on: September 16, 2022
Ayeh Shamsadini1, Fatemeh Fakhrabadi1, Darya Shamsadini1
1Clinical Research Development Unit, Shafa Hospital, Kerman University of Medical Sciences, Kerman, Iran.
Background:
Mucormycosis, commonly known as 'black fungus,' has emerged as a significant health threat during the COVID-19 pandemic, with a marked increase in prevalence among infected individuals. This study focuses on identifying the characteristics of COVID-19-associated mucormycosis patients in Kerman.
Methods:
This cross-sectional study was conducted at Shafa Hospital, Kerman, in 2022, following ethical approval from Kerman University of Medical Sciences. Patients with confirmed mucormycosis and positive COVID-19 PCR results were included using a census method. Diagnosis involved PCR testing, histopathological examination, and imaging studies. Data were collected from medical records by a trained student, ensuring anonymity. SPSS version 25 was used for analysis, with significance set at p < 0.05.
Results:
Among 37 patients with COVID-19-associated mucormycosis in 2022, 34 had complete medical records. The mean age was 58.8 ± 17.2 years, with a gender distribution of 58.8% female and 41.2% male. Mucormycosis was diagnosed 2-4 weeks after COVID-19 infection in 55.9% of cases. Pulmonary involvement was noted in 97.1% of patients, and corticosteroid use was prevalent in 85.3%. Diabetes and hypertension were present in 64.7% and 35.3% of patients, respectively. Opioid use was significantly higher in males (75.0%) compared to females (25.0%) (P = 0.042).
Conclusions:
This study reveals a higher prevalence of mucormycosis among older adults and individuals with underlying health conditions, particularly those who are immunocompromised, following COVID-19. The timing of diagnosis suggests a link between COVID-19-related immune compromise and mucormycosis onset, highlighting the need for vigilant monitoring during recovery. The significant pulmonary involvement underscores the necessity for routine respiratory screenings in at-risk populations. Additionally, the higher opioid use among males indicates a need to reassess pain management protocols to consider their impact on immune function. Understanding these patterns can inform targeted interventions to improve patient outcomes in diverse healthcare settings.
Related Concept Videos
Fungal Group Zygomycota
Fungal Phylum Microsporidia
Atypical Pneumonia
Cytomegalovirus Disease
Cryptococcal Meningitis
Candidiasis